Hong Kong-listed Chinese drug manufacturers are approaching profitability through robust sales growth and international licensing arrangements, signaling a sector recovery that institutional investors are monitoring for digital asset exposure opportunities. The pharmaceutical industry’s pivot toward profitability after years of R&D spending aligns with growing institutional interest in healthcare blockchain applications and tokenized IP rights.